Turkey-based digital health startup h2o therapeutics has announced it has received FDA-Clearance for its prescription mobile app Parky for monitoring Parkinson's Disease. Limited to the Apple Watch only, the Parky app monitors in real-time Parkinson's disease symptoms such as tremors and dyskinesia (the uncontrolled, involuntary movements that affect people with Parkinson's disease).
Engineers at Stanford University, Georgia Tech, USC Viterbi School of Engineering, and the University of Tokyo have developed a new digital oncology wearable with a...
Transparency and data are essential to the evolution of health care. A recent review of patient perspectives on data privacy shows continued uncertainty over the...
With much of health and health care moving onto digital platforms, there has been remarkable growth in the amount of information generated.AI applications can potentially create $150 billion in annual savings for the US healthcare economy by 2026. These cost savings potential is one reason why healthcare organizations will continue to invest in digital solutions to deliver new sources of value over the foreseeable future; whether its to lower the cost of care, improve labor productivity, enable better patient/customer experiences, or another desired outcome.
Hinge Health, a Digital Musculoskeletal Clinic™, has released its 2022 State of Musculoskeletal (MSK) Health Report showing many pressing trends affecting MSK care in America. This second edition report highlights care inequities based on race, gender, location, the growing economic burden for employers, and the connection between chronic pain and mental health. Additionally, the findings highlight reducing access-to-care barriers while expanding whole-person care.
OncoHost, a developer in next-generation precision oncology technology for improved personalized cancer therapy, announces the closing of a $35 million Series C funding round. According to the announcement, funding will expand OncoHost's ongoing multicenter PROPHETIC trial, which utilizes PROphet®, the company's machine learning-based host response profiling platform, and support the coming U.S. commercial launch of the precision oncology diagnostic solution.
